Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;80(13):1345-1353.
doi: 10.1007/s40265-020-01374-0.

Lurbinectedin: First Approval

Anthony Markham  1
Affiliations
Review

Lurbinectedin: First Approval

Anthony Markham. Drugs. 2020 Sep.

Abstract

The oncogenic transcription inhibitor lurbinectedin (ZEPZELCA™) is being developed by PharmaMar as a treatment for various cancers. The drug has been granted orphan drug status for the treatment of small cell lung cancer (SCLC) by regulatory authorities in multiple countries worldwide and was approved in the USA in June 2020 for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy. The US FDA and international regulators, including the Australian Therapeutic Goods Administration, are collaborating on the review of lurbinectedin under the Project Orbis initiative. Clinical investigation in other solid cancers is ongoing. This article summarizes the milestones in the development of lurbinectedin leading to this first approval for the treatment of metastatic SCLC.

PubMed Disclaimer

References

    1. PharmaMar. Oncology pipeline. 2020. https://pharmamar.com/science-and-innovation/oncology-pipeline/?lang=en . Accessed 6 Jul 2020.
    1. Leal JF, Martínez-Díez M, García-Hernández V, et al. PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol. 2010;161(5):1099–110. - PubMed - PMC - DOI
    1. Xie W, Forveille S, Iribarren K, et al. Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity. Oncoimmunology. 2019;8(11):e1656502. - PubMed - PMC - DOI
    1. Belgiovine C, Bello E, Liguori M, et al. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer. 2017;117(5):628–38. - PubMed - PMC - DOI
    1. PharmaMar. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PharmaMar's lurbinectedin [media release]. 3 Aug 2018. https://www.pharmamar.com .

MeSH terms

LinkOut - more resources